Interview with Krisja Vermeylen, Vice President Novo Nordisk France &…
Novo Nordisk just celebrated 50 years in France; what have been some of the more recent events that have marked the…
Novo Nordisk France
Last updated: 13.02.2014
Address: Coeur Défense, Tour B 100, Esplanade Charles de Gaulle, 92932 La Défense Cedex
Tel: 01 41 97 66 00
Web: http://www.novonordisk.fr/documents/home_page/document/index.asp
Company description
Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries.
Products and services
Haemophilia care, growth hormone therapy and hormone replacement therapy.
Interviews
Related
France / Germany Production Alliance Falters; Sanofi Vaccine Enters Phase III Trials; Valneva Still in the Vaccine Race
The latest news from French pharma, including why President Emmanuel Macron’s initiative to bring medical…
COVID-19 Vaccines / Valneva: A Success Story for France?
While Big Pharma companies like Pfizer, Janssen and AstraZeneca, have grabbed the headlines over the past year for…
France / ‘Humiliation’ & the Sanofi-Pfizer Vaccine Deal; AntiVax Struggles; Servier’s Neurology Push
The latest from French pharma where Sanofi has inked a deal to produce 125 million doses of Pfizer’s COVID-19…
France / Mid-2021 for Sanofi COVID-19 Vaccine; 1 Million Domestic Cases; Ipsen Growth
A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how…
News Roundup / French Pharma August 2020
A roundup of some of the latest from French pharma, including Sanofi’s bumper Prinicipia deal, how Unither’s…
M&A / Sanofi Buys Principia for USD 3.7 Billion as Part of Specialty Pivot
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in…
Sanofi / Thomas Triomphe Appointed Executive Vice President of Vaccines Unit
With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe…
Mid-Cap Strategies / LFB USA CEO Optimistic on Hemophilia Launches Amid COVID Crisis
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA…
Sanofi / USD 679 Million Investment in French Vaccine Manufacturing
French pharma giant Sanofi is pivoting its focus to invest more heavily in vaccines with a plan to invest USD 679…
Ipsen / New CEO as David Loew Makes Switch From Sanofi Pasteur
David Loew, formerly executive vice president of Sanofi Pasteur, Sanofi’s vaccines division, was appointed…
Europe / A New Approach to Health Crises in France & Germany
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would…
COVID-19 Vaccine / Sanofi CEO Paul Hudson Commits to "Bring a Solution to Everybody, Everywhere"
In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the…
